US Patent Term Extension – Protecting Innovation Beyond the 20-Year Limit


 

In high-investment industries like pharma and biotech, years can be lost waiting for regulatory approvals. The US Patent Term Extension (PTE) offers a lifeline—recovering that time and extending market exclusivity.

Why it matters now:

  • Recover lost years: Add up to 5 years to a patent term.

  • Fair protection: Ensures at least 14 years of exclusivity post-approval.

  • Life sciences edge: Covers drugs, biologics, and medical devices hit hardest by FDA review delays.

  • Critical ROI: Every extra day of exclusivity can mean millions in revenue.

Compared to PTA (delays during prosecution) or SPCs (Europe), PTE is uniquely tailored to regulatory hurdles in the US—making it an essential strategy for innovators navigating FDA timelines.

💡 Stay ahead in patent strategy—read the full blog to explore how PTE safeguards your IP investment.
👉 US Patent Term Adjustments - Extending Patent Life Through Strategic Prosecution - PatSeer



Comments

Popular posts from this blog

Open Innovation vs. In-House R & D: Finding the Sweet Spot for Startups

U.S. Renewable Energy Patent Trends (2015–2025): A Snapshot from PatSeer Analytics